We are live on ! Find out more
ABUS icon

Arbutus Biopharma
ABUS

167 hedge funds and large institutions have $626M invested in Arbutus Biopharma in 2026 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 48 increasing their positions, 48 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

7.72% more ownership

Funds ownership: 63.45% → 71.16% (+7.7%)

7% more capital invested

Capital invested by funds: $587M → $626M (+$39M)

0% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 48

3% less first-time investments, than exits

New positions opened: 29 | Existing positions closed: 30

3% less funds holding

Funds holding: 172 → 167 (-5)

20% less call options, than puts

Call options by funds: $2.67M | Put options by funds: $3.34M

40% less funds holding in top 10

Funds holding in top 10: 5 → 3 (-2)

Holders
167
Holders Change
-5
Holders Change %
-2.91%
% of All Funds
2.06%
Holding in Top 10
3
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-40%
% of All Funds
0.04%
New
29
Increased
48
Reduced
48
Closed
30
Calls
$2.67M
Puts
$3.34M
Net Calls
-$671K
Net Calls Change
-$10.2M

Top Buyers

1
TSC
Two Seas Capital
New York
+$26.1M
2
RCMNY
Rubric Capital Management (New York)
New York
+$22.1M
3
Barclays
Barclays
United Kingdom
+$17.3M
4
Legal & General Group
Legal & General Group
United Kingdom
+$9.96M
5
JFG
Jefferies Financial Group
New York
+$8.28M

Top Sellers

1
ACM
ADAR1 Capital Management
Texas
-$9.98M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$7.32M
3
SC
Stempoint Capital
New York
-$4.75M
4
Morgan Stanley
Morgan Stanley
New York
-$3.55M
5
SCM
Saba Capital Management
New York
-$1.67M
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of Montreal
26
Bank of Montreal
Ontario, Canada
$3.52M +$70.4K +16,107 +2%
Citadel Advisors
27
Citadel Advisors
Florida
$3.05M +$2.5M +572,295 +546%
Millennium Management
28
Millennium Management
New York
$2.89M +$2.81M +642,448 New
WSL
29
Western Standard LLC
California
$2.35M +$60.1K +13,734 +3%
QOP
30
Quinn Opportunity Partners
Virginia
$2.32M – – –
RC
31
Rangeley Capital
Connecticut
$2.25M -$1.49M -340,000 -40%
FCH
32
Freestone Capital Holdings
Washington
$1.99M – – –
Wellington Management Group
33
Wellington Management Group
Massachusetts
$1.98M -$146K -33,437 -7%
KCM
34
Kennedy Capital Management
Missouri
$1.77M -$490K -111,962 -22%
Bank of New York Mellon
35
Bank of New York Mellon
New York
$1.71M -$37.3K -8,541 -2%
UBS Group
36
UBS Group
Switzerland
$1.64M +$950K +217,179 +147%
Hudson Bay Capital Management
37
Hudson Bay Capital Management
Connecticut
$1.57M -$1.42M -325,000 -48%
Swiss National Bank
38
Swiss National Bank
Switzerland
$1.28M – – –
LWA
39
Ledgewood Wealth Advisors
New Hampshire
$1.25M – – –
N
40
Nuveen
North Carolina
$1.17M +$4.74K +1,083 +0.4%
CCA
41
Carrera Capital Advisors
Michigan
$1.13M +$1.1M +252,159 New
Invesco
42
Invesco
Georgia
$1.12M +$2.93K +671 +0.3%
Susquehanna International Group
43
Susquehanna International Group
Pennsylvania
$1.09M +$580K +132,559 +121%
APM
44
Avidity Partners Management
Texas
$1.09M +$1.09M +250,000 New
Raymond James Financial
45
Raymond James Financial
Florida
$861K +$574K +131,170 +218%
RhumbLine Advisers
46
RhumbLine Advisers
Massachusetts
$805K -$19.5K -4,465 -2%
Deutsche Bank
47
Deutsche Bank
Germany
$723K +$89.8K +20,542 +15%
Fidelity Investments
48
Fidelity Investments
Massachusetts
$653K +$37.5K +8,570 +6%
D.E. Shaw & Co
49
D.E. Shaw & Co
New York
$644K -$387K -88,562 -38%
California State Teachers Retirement System (CalSTRS)
50
California State Teachers Retirement System (CalSTRS)
California
$643K -$4.92K -1,125 -0.8%
1
2
3 4 5

ABUS Hedge Fund Activity: Q1 2026 in Review

167 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q1 2026, worth a combined $626M — up 6.7% from $587M a quarter earlier.

Sellers outnumbered buyers: 30 funds closed out of ABUS and 29 opened new positions — a net loss of 1 holder — while 48 trimmed existing stakes and 48 added.

The largest buyer was Two Seas Capital, adding an estimated $26.1M. The largest seller was ADAR1 Capital Management, cutting an estimated $9.98M.

  • 167 institutional investors held Arbutus Biopharma (ABUS) as of Q1 2026, down from 172 in Q4 2025.
  • Funds reported $626M of Arbutus Biopharma stock for Q1 2026, up 6.7% quarter-over-quarter.
  • 29 funds opened new Arbutus Biopharma positions in Q1 2026 and 30 closed out, a net change of -1 holder.
  • The largest Arbutus Biopharma buyer in Q1 2026 was Two Seas Capital, an estimated $26.1M added.
  • The largest Arbutus Biopharma seller in Q1 2026 was ADAR1 Capital Management, an estimated $9.98M sold.

Based on aggregated 13F filings for Q1 2026.